文献速递艾滋病与性传播感染

静脉青霉素G与肌注普鲁卡因青霉素联合口服丙磺舒治疗神经梅毒结局比较

Neurosyphilis Treatment Outcomes After Intravenous Penicillin G Versus Intramuscular Procaine Penicillin Plus Oral Probenecid.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究纳入2003年4月至2014年5月在华盛顿大学因怀疑神经梅毒转诊且脑脊液异常的150例梅毒患者,比较静脉水剂青霉素G与肌注水剂普鲁卡因青霉素G联合口服丙磺舒的脑脊液/血清指标正常化情况,发现两种方案疗效无差异,且与HIV状态无关。

要点

  • 静脉青霉素G与肌注普鲁卡因青霉素联合丙磺舒治疗神经梅毒,脑脊液指标正常化无差异。
  • HIV状态不影响神经梅毒治疗后脑脊液或血清指标的正常化 likelihood。
  • HIV感染者中,使用抗逆转录病毒治疗者脑脊液白细胞和VDRL更易正常化。

核心结论

  • 在当前抗逆转录病毒治疗时代,静脉青霉素G与肌注普鲁卡因青霉素联合丙磺舒治疗神经梅毒的结局无差异,且不受HIV状态影响。

研究设计与样本

  • 研究纳入2003年4月至2014年5月在华盛顿大学进行的梅毒脑脊液异常研究中的150例脑脊液异常且接受PenG或APPG-P治疗的患者。
  • 脑脊液异常定义为白细胞计数>20/µL、脑脊液蛋白>50 mg/dL或脑脊液VDRL试验反应性。
  • 采用Cox回归确定脑脊液或血清指标正常化的风险比。

主要发现

  • 接受PenG或APPG-P治疗者,脑脊液白细胞和脑脊液VDRL反应性在治疗后12个月内正常化,蛋白正常化更慢且不完全。
  • 治疗方案或HIV状态与任何指标正常化的可能性无关。
  • HIV感染者中,使用抗逆转录病毒治疗者脑脊液白细胞计数和脑脊液VDRL反应性更可能正常化。
  • 意外发现,CD4+ T细胞计数低者脑脊液白细胞更可能正常化;当神经梅毒严格定义为脑脊液VDRL反应性时,与CD4+ T细胞计数的关系不变。

关键数值与推荐

  • 脑脊液异常诊断标准:白细胞计数>20/µL、蛋白>50 mg/dL或脑脊液VDRL反应性。
  • 脑脊液白细胞和脑脊液VDRL反应性在治疗后12个月内正常化,蛋白正常化更慢且不完全。

临床怎么用

  • 神经梅毒治疗可考虑静脉青霉素G或肌注普鲁卡因青霉素联合丙磺舒,两者结局无差异。
  • HIV感染者接受抗逆转录病毒治疗可能改善脑脊液白细胞和VDRL的正常化。
  • 脑脊液白细胞正常化与CD4+ T细胞计数的关系提示神经梅毒诊断标准可能受HIV相关脑脊液细胞增多影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data comparing neurosyphilis treatment regimens are limited. METHODS: Participants were enrolled in a study of cerebrospinal fluid (CSF) abnormalities in syphilis that was conducted at the University of Washington between April 2003 to May 2014. They were diagnosed with syphilis and referred by their providers due to concerns for neurosyphilis. We evaluated 150 people with CSF abnormalities who were treated with either intravenous aqueous penicillin G (PenG) or intramuscular aqueous procaine penicillin G plus oral probenecid (APPG-P). An abnormal CSF diagnosis was defined as a white blood cell (WBC) count >20/µL, a CSF protein reading >50 mg/dL, or a reactive CSF-Venereal Disease Research Laboratory test (VDRL). Hazard ratios for normalization of CSF or serum measures were determined using Cox regression. RESULTS: In individuals treated with either PenG or APPG-P, CSF WBCs and CSF-VDRL reactivity normalized within 12 months after treatment, while protein normalized more slowly and less completely. There was no relationship between treatment regimen or human immunodeficiency virus (HIV) status and likelihood of normalization of any measure. Among those living with HIV, CSF WBC counts and CSF-VDRL reactivity were more likely to normalize in those treated with antiretrovirals. Unexpectedly, CSF WBCs were more likely to normalize in those with low CD4+ T cell counts. When neurosyphilis was more stringently defined as a reactive CSF-VDRL, the relationship with the CD4+ T cell count remained unchanged. CONCLUSIONS: In the current antiretroviral treatment era, neurosyphilis treatment outcomes are not different for PenG and APPG-P, regardless of HIV status. The relationship between the normalization of CSF WBC counts and CD4+ T cell counts may indicate continued imprecision in neurosyphilis diagnostic criteria, due to HIV-related CSF pleocytosis.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dunaway SB, Maxwell CL, Tantalo LC, et al. Neurosyphilis Treatment Outcomes After Intravenous Penicillin G Versus Intramuscular Procaine Penicillin Plus Oral Probenecid. Clin Infect Dis. 2020. PMID: 31504293. doi:10.1093/cid/ciz795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。